Biogen (BIIB) Stock Price

Biogen Price

NASDAQ·CLOSED
209.83USD-0.82 (-0.39 %)
Market closed

Revenue has compounded at 7.1% per year over the past 19 years to 9.89 B USD. Earnings per share have grown at 14.9% per year over the last 19 years. Biogen's net margin stands at 13.1%, down from 14.2% several years earlier. Analysts set a median price target of 210.12 USD, implying 0.1% above the current price. Of 42 analysts, 20 rate the stock a buy — an overall Hold consensus. The stock trades about 59% above its 52-week low.

Biogen stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Biogen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biogen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biogen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biogen Stock Price History
DateBiogen Price
8/14/2026209.83 USD
8/13/2026210.65 USD
8/12/2026208.87 USD
8/11/2026203.89 USD
8/10/2026207.71 USD
8/7/2026207.94 USD
8/6/2026206.28 USD
8/5/2026207.06 USD
8/4/2026206.68 USD
8/3/2026201.82 USD
7/31/2026202.95 USD
7/30/2026207.93 USD
7/29/2026215.73 USD
7/27/2026203.56 USD
7/23/2026200.62 USD
7/22/2026197.74 USD
7/21/2026203.16 USD
7/20/2026199.95 USD
7/17/2026205.99 USD
7/16/2026208.92 USD
7/15/2026197.24 USD
7/14/2026191.95 USD
7/13/2026202.48 USD
7/10/2026199.15 USD
7/9/2026198.91 USD
7/8/2026205.78 USD
7/7/2026205.70 USD
7/6/2026213.92 USD
7/2/2026216.12 USD
7/1/2026209.74 USD
6/30/2026216.06 USD
6/29/2026216.71 USD
6/26/2026216.03 USD
6/25/2026201.96 USD
6/24/2026199.59 USD
6/23/2026197.19 USD
6/22/2026195.57 USD
6/18/2026194.37 USD
6/17/2026199.48 USD
6/16/2026194.25 USD
6/15/2026198.85 USD
6/12/2026202.68 USD
6/11/2026198.55 USD
6/10/2026197.11 USD
6/9/2026199.10 USD
6/8/2026192.62 USD
6/5/2026199.84 USD
6/4/2026198.62 USD
6/3/2026191.09 USD
6/2/2026187.80 USD
6/1/2026193.42 USD
5/29/2026197.99 USD
5/28/2026195.67 USD
5/27/2026198.95 USD
5/26/2026195.08 USD
5/22/2026192.41 USD
5/21/2026186.41 USD
5/20/2026188.43 USD
5/19/2026190.56 USD
5/18/2026191.91 USD
5/15/2026192.95 USD
5/14/2026191.37 USD
5/13/2026204.53 USD
5/12/2026199.36 USD
5/11/2026197.95 USD
5/8/2026193.45 USD
5/7/2026191.38 USD
5/6/2026190.68 USD
5/5/2026189.13 USD
5/4/2026187.21 USD
5/1/2026187.06 USD
4/30/2026189.28 USD
4/29/2026194.38 USD
4/28/2026183.38 USD
4/27/2026180.67 USD
4/24/2026184.38 USD
4/23/2026187.88 USD
4/22/2026190.07 USD
4/21/2026185.95 USD
4/20/2026183.34 USD
4/17/2026177.35 USD
4/16/2026176.02 USD
4/15/2026180.54 USD
4/14/2026178.96 USD
4/13/2026176.37 USD
4/10/2026172.97 USD
4/9/2026177.11 USD
4/8/2026179.90 USD
4/7/2026175.61 USD
4/6/2026172.34 USD
4/2/2026177.34 USD
4/1/2026183.78 USD
3/31/2026183.33 USD
3/30/2026187.57 USD
3/27/2026183.84 USD
3/26/2026191.06 USD
3/25/2026189.18 USD
3/24/2026184.02 USD
3/23/2026183.64 USD
3/20/2026181.46 USD
3/19/2026187.27 USD
3/18/2026182.31 USD
3/17/2026182.31 USD
3/16/2026185.29 USD
3/15/2026183.26 USD
3/13/2026181.55 USD
3/12/2026181.55 USD
3/11/2026184.90 USD
3/10/2026190.48 USD
3/9/2026188.41 USD
3/8/2026188.24 USD
3/6/2026184.87 USD
3/5/2026184.87 USD
3/4/2026188.08 USD
3/3/2026189.94 USD
3/2/2026184.02 USD
3/1/2026188.05 USD
2/27/2026191.82 USD
2/26/2026191.82 USD
2/25/2026188.02 USD
2/24/2026190.73 USD
2/23/2026195.13 USD
2/22/2026196.34 USD
2/20/2026192.03 USD
2/19/2026192.03 USD
2/18/2026192.08 USD
2/17/2026194.13 USD
2/16/2026195.62 USD
2/13/2026196.52 USD
2/12/2026196.52 USD
2/11/2026195.50 USD
2/10/2026191.20 USD
2/9/2026188.99 USD
2/8/2026193.81 USD
2/6/2026201.18 USD
2/5/2026201.18 USD
2/4/2026185.36 USD
2/3/2026185.45 USD
2/2/2026176.76 USD
2/1/2026179.09 USD
1/30/2026179.89 USD
1/29/2026179.89 USD
1/28/2026176.18 USD
1/27/2026174.83 USD
1/26/2026174.12 USD
1/25/2026173.12 USD
1/23/2026171.59 USD
1/22/2026171.59 USD
1/21/2026173.80 USD
1/20/2026172.62 USD
1/19/2026165.38 USD
1/16/2026164.42 USD
1/15/2026164.42 USD
1/14/2026168.57 USD
1/13/2026169.31 USD
1/12/2026178.30 USD
1/11/2026185.63 USD
1/9/2026187.62 USD
1/8/2026187.62 USD
1/7/2026186.00 USD
1/6/2026186.91 USD
1/5/2026182.61 USD
1/4/2026174.63 USD
1/2/2026177.82 USD
1/1/2026177.82 USD
12/31/2025175.99 USD
12/30/2025175.99 USD
12/29/2025176.40 USD
12/28/2025176.83 USD
12/26/2025177.08 USD
12/25/2025177.08 USD
12/24/2025176.33 USD
12/23/2025176.33 USD
12/22/2025174.82 USD
12/21/2025174.70 USD
12/19/2025174.80 USD
12/18/2025174.80 USD
12/17/2025169.91 USD
12/16/2025172.10 USD
12/15/2025171.50 USD
12/14/2025175.74 USD
12/12/2025174.10 USD
12/11/2025174.10 USD
12/10/2025172.50 USD
12/9/2025177.55 USD
12/8/2025175.84 USD
12/7/2025180.44 USD
12/5/2025181.30 USD
12/4/2025181.30 USD
12/3/2025181.98 USD
12/2/2025180.75 USD
12/1/2025180.18 USD
11/30/2025177.78 USD
11/28/2025182.09 USD
11/27/2025182.09 USD
11/26/2025181.94 USD
11/25/2025181.94 USD
11/24/2025181.96 USD
11/23/2025176.82 USD
11/21/2025175.30 USD
11/20/2025175.30 USD
11/19/2025168.18 USD
11/18/2025167.93 USD
11/17/2025168.83 USD
11/16/2025164.68 USD
11/14/2025167.55 USD
11/13/2025167.55 USD
11/12/2025164.73 USD
11/11/2025161.48 USD
11/10/2025159.56 USD
11/9/2025156.26 USD
11/7/2025155.51 USD
11/6/2025155.51 USD
11/5/2025156.74 USD
11/4/2025153.43 USD
11/3/2025149.33 USD
11/2/2025151.44 USD
10/31/2025154.27 USD
10/30/2025154.27 USD
10/29/2025149.61 USD
10/28/2025147.86 USD
10/27/2025149.13 USD
10/26/2025150.43 USD
10/23/2025149.89 USD
10/22/2025150.08 USD
10/21/2025147.72 USD
10/20/2025146.22 USD
10/19/2025146.63 USD
10/16/2025143.00 USD
10/15/2025142.26 USD
10/14/2025143.66 USD
10/13/2025145.31 USD
10/12/2025144.69 USD
10/9/2025146.57 USD
10/8/2025149.61 USD
10/7/2025150.97 USD
10/6/2025152.21 USD
10/5/2025154.05 USD
10/2/2025159.88 USD
10/1/2025155.25 USD
9/30/2025154.22 USD
9/29/2025140.08 USD
9/28/2025138.52 USD
9/25/2025137.37 USD
9/24/2025135.67 USD
9/23/2025137.67 USD
9/22/2025139.31 USD
9/21/2025140.66 USD
9/18/2025142.50 USD
9/17/2025143.81 USD
9/16/2025144.87 USD
9/15/2025143.68 USD
9/14/2025143.32 USD
9/11/2025144.86 USD
9/10/2025148.84 USD
9/9/2025142.61 USD
9/8/2025143.60 USD
9/7/2025141.35 USD
9/4/2025140.67 USD
9/3/2025139.94 USD
9/2/2025141.62 USD
9/1/2025139.63 USD
8/28/2025132.22 USD
8/27/2025132.65 USD
8/26/2025136.36 USD
8/25/2025136.72 USD
8/24/2025136.36 USD
8/21/2025139.31 USD
8/20/2025139.12 USD
8/19/2025138.99 USD
Access this data via the Eulerpool API
Get Free API Key

Biogen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
9.84 B USD
2.17 B USD
1.16 B USD
Jan 1, 2024
9.68 B USD
2.65 B USD
1.63 B USD
Jan 1, 2025
9.89 B USD
2.79 B USD
1.29 B USD
Jan 1, 2026 (e)
10.04 B USD
2.53 B USD
1.91 B USD
Jan 1, 2027 (e)
10.28 B USD
2.59 B USD
2.40 B USD
Jan 1, 2028 (e)
10.54 B USD
2.66 B USD
2.70 B USD
Jan 1, 2029 (e)
10.79 B USD
2.72 B USD
2.90 B USD
Jan 1, 2030 (e)
11.12 B USD
2.80 B USD
3.06 B USD

Biogen Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 19, 2026, 5:43 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
11.4512.2713.4514.3813.4510.9810.179.849.689.8910.0410.2810.5410.7911.129.55
6.367.219.616.88-6.49-18.32-7.37-3.32-1.632.221.532.362.542.373.02-14.13
87.0886.7286.5086.4086.5780.7977.6175.5177.1875.9975.9975.9975.9975.9975.9975.99
9.9710.6411.6412.4211.648.877.907.437.477.527.637.818.018.208.457.25
5.665.586.577.564.983.503.222.172.652.792.532.592.662.722.80–
49.4445.4448.8052.5737.0031.8231.6922.1027.4028.2325.2325.2325.2325.2325.23–
3.702.544.435.894.001.563.051.161.631.291.912.402.702.903.062.72
4.40-31.4374.5232.90-32.06-61.1195.82-61.9040.57-20.8347.6025.8012.467.345.73-11.30
219.00213.00205.00187.00161.00150.00146.00145.60145.90147.10147.10147.10147.10147.10147.10147.10
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biogen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biogen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biogen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biogen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biogen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biogen stock margins

The Biogen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biogen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biogen.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
80.79 %
31.82 %
14.17 %
Jan 1, 2022
77.61 %
31.69 %
29.95 %
Jan 1, 2023
75.51 %
22.11 %
11.81 %
Jan 1, 2024
77.18 %
27.40 %
16.87 %
Jan 1, 2025
75.99 %
28.23 %
13.07 %
Jan 1, 2026 (e)
75.99 %
25.23 %
19.00 %
Jan 1, 2027 (e)
75.99 %
25.23 %
23.35 %
Jan 1, 2028 (e)
75.99 %
25.23 %
25.60 %

Biogen Stock Revenue, EBIT, Earnings per Share

The Biogen earnings per share therefore indicates how much revenue Biogen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
73.21 USD
23.30 USD
10.37 USD
Jan 1, 2022
69.68 USD
22.08 USD
20.87 USD
Jan 1, 2023
67.55 USD
14.93 USD
7.97 USD
Jan 1, 2024
66.32 USD
18.17 USD
11.19 USD
Jan 1, 2025
67.24 USD
18.98 USD
8.79 USD
Jan 1, 2026 (e)
68.26 USD
17.22 USD
12.97 USD
Jan 1, 2027 (e)
69.87 USD
17.63 USD
16.31 USD
Jan 1, 2028 (e)
71.65 USD
18.08 USD
18.34 USD

Biogen business model & stock analysis

Biogen Inc. is an American biotechnology company specializing in the development, manufacturing, and marketing of therapeutics for neurodegenerative diseases, autoimmune diseases, and hemophilia. The company was founded in 1978 and is a Fortune 500 company headquartered in Cambridge, Massachusetts. It employs over 7,000 employees worldwide. The origins of Biogen can be traced back to its founding by Charles Weissmann, a Swiss biology professor, and American entrepreneurs Walter Gilbert and Phillip Sharp. The company initially focused on the development of interferon, a protein that protects the body against viruses. However, in the late 1980s, Biogen shifted its research and development efforts towards neurodegenerative diseases. Biogen's business model is based on the discovery and development of new and unique treatments for serious diseases. Through research, the discovery of new compounds, as well as acquisitions and partnerships with other companies, Biogen continually expands its product pipeline. The company also has a strong presence in the global market, selling its products in over 90 countries worldwide. Biogen has sought to expand into multiple areas of the biopharmaceutical industry. The company is divided into three main business areas: neurology, immunology, and hemophilia. In the neurology field, Biogen is a leading provider of drugs for the treatment of severe diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. The company has developed several innovative therapeutics that can either slow down or even halt the progression of these diseases. One example is the drug Aduhelm®, which recently gained approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer's and garnered worldwide attention. In the immunology field, Biogen offers medications for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Biogen is also a major provider of biosimilars, which are replicas of biopharmaceutical drugs developed and manufactured by other companies. Biosimilars can help reduce the cost of patient treatment, particularly in countries with limited healthcare resources. In the hemophilia field, Biogen's offerings include a range of products and services specifically developed for patients with hemophilia. These include clotting factor preparations for the treatment of bleeding, novel clotting factors, and specialized clotting tests. Biogen also invests significantly in the research of new technologies and platforms. The company has formed partnerships with other leading biotech companies such as Ionis Pharmaceuticals and Sangamo Therapeutics to develop innovative technologies like antisense oligonucleotides, genome editing, and gene silencing. Biogen is also a founding member of BioNTech, a German biotechnology company known for its development of mRNA-based vaccines for cancer and infectious diseases. Overall, Biogen has an impressive track record in the development of innovative therapeutics for complex diseases. The company has a strong presence in the global market and aims to expand its product pipeline through research and partnerships. With its high commitment to innovation, Biogen is well-positioned to play a significant role in the biopharmaceutical industry in the future.

Biogen SWOT Analysis

Strengths

Biogen Inc is a prominent biotechnology company with a strong presence in the industry. It has a solid track record of developing innovative drugs and therapies.

Biogen Inc offers a diversified range of products, including treatments for multiple sclerosis, spinal muscular atrophy, and hemophilia. This diversified portfolio reduces its dependency on a single product and contributes to its overall revenue stability.

The company invests significantly in research and development, allowing it to stay at the forefront of medical advancements and develop cutting-edge therapies.

Weaknesses

Biogen Inc heavily relies on a few key products, such as Tecfidera and Spinraza, for a significant portion of its revenue. This creates vulnerability if any of these products face challenges or competition.

As a biotechnology company, Biogen Inc faces regulatory risks associated with drug approvals and ongoing compliance. Changes in regulatory policies can impact the company's ability to bring new products to market or maintain existing product lines.

Opportunities

The global biopharmaceutical market is expanding rapidly, providing significant growth opportunities for Biogen Inc. The company can leverage its expertise and expand into new regions to capture a larger market share.

Biogen Inc can benefit from investing in innovative technologies, such as gene therapies and personalized medicine. These advancements have the potential to revolutionize the healthcare industry and offer new avenues for growth.

Threats

Biogen Inc operates in a highly competitive industry with several other major pharmaceutical and biotechnology companies. Intense competition can impact pricing, market share, and profitability.

Protecting intellectual property rights is crucial for Biogen Inc, as competitors may attempt to replicate or challenge its products. Any infringement or loss of intellectual property could negatively impact the company's revenue and market position.

Biogen Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Biogen Employees
Details
Date
Biogen Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Biogen Segments

Biogen Revenue by Segment (1/17)

  • Max

Product revenue, net
Revenue from anti-CD20 therapeutic programs
Contract manufacturing, royalty and other revenue
Alzheimer's collaboration revenue
Details
Date
Product, net
Product revenue, net
Revenues from anti-CD20 therapeutic programs
Revenue from anti-CD20 therapeutic programs
Contract manufacturing, royalty and other revenue
Other
Alzheimer's collaboration revenue
Jan 1, 2024
0.00 USD
7.21 B USD
0.00 USD
1.75 B USD
652.60 M USD
0.00 USD
59.90 M USD
Jan 1, 2025
0.00 USD
7.12 B USD
0.00 USD
1.86 B USD
732.90 M USD
0.00 USD
177.70 M USD

Biogen Revenue by Segment (2/17)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Subtotal: Multiple Sclerosis
TECFIDERA
Subtotal: Rare Disease
TYSABRI
SPINRAZA
Total Fumarate
Total Interferon
AVONEX
Subtotal: Biosimilars
VUMERITY
Biosimilars
BENEPALI
Other
Other corporate
Contract manufacturing and other revenue
PLEGRIDY
IMRALDI
FAMPYRA
QALSODY
FLIXABI
Completed technology for SKYCLARYS (U.S.)
BYOOVIZ
ZINBRYTA
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Biogen Revenue by Segment (3/17)

  • Max

Subtotal: Multiple Sclerosis
Subtotal: Rare Disease
Total Fumarate
Total Interferon
Subtotal: Biosimilars
Other
Details
Date
Subtotal: Multiple Sclerosis
Revenues from anti-cd20 therapeutic programs
Subtotal: Rare Disease
Total Fumarate
Royalty Attributed To OCREVUS
Total Interferon
Contract manufacturing revenue
Subtotal: Biosimilars
Other
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
4.04 B USD
0.00 USD
2.15 B USD
1.43 B USD
0.00 USD
945.60 M USD
0.00 USD
729.10 M USD
197.20 M USD

Biogen Revenue by Segment (4/17)

  • Max

Subtotal: Multiple Sclerosis
Subtotal: Rare Disease
Total Fumarate
Total Interferon
Subtotal: Biosimilars
Other
Details
Date
Subtotal: Multiple Sclerosis
TECFIDERA
Subtotal: Rare Disease
Total Fumarate
Royalty revenue on sales of OCREVUS
Total Interferon
Subtotal: Biosimilars
Other
Royalty revenue
Royalty
Jan 1, 2024
4.35 B USD
0.00 USD
1.99 B USD
1.60 B USD
0.00 USD
968.00 M USD
793.10 M USD
82.50 M USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Biogen Revenue by Segment (5/17)

  • Max

Royalty revenue on sales of OCREVUS
Contract manufacturing revenue
Details
Date
Royalty revenue on sales of OCREVUS
Contract manufacturing revenue
Other revenue
Royalty and other revenue
Jan 1, 2024
0.00 USD
592.10 M USD
0.00 USD
0.00 USD
Jan 1, 2025
1.41 B USD
0.00 USD
0.00 USD
0.00 USD

Biogen Revenue by Segment (6/17)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Subtotal: MS
TECFIDERA
Interferon
TYSABRI
Fumarate
SPINRAZA
AVONEX
Subtotal: Biosimilars
VUMERITY
BENEPALI
PLEGRIDY
IMRALDI
FAMPYRA
FLIXABI
BYOOVIZ
FUMADERM
ADUHELM
ZINBRYTA
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Biogen Revenue by Segment (7/17)

  • Max

Royalty and other revenue
Details
Date
TYSABRI
Royalty and other revenue
Jan 1, 2024
0.00 USD
60.50 M USD
Jan 1, 2025
0.00 USD
0.00 USD

Biogen Revenue by Segment (8/17)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
MS Product Revenues
Interferon
BENEPALI
FAMPYRA
FLIXABI
FUMADERM
ALPROLIX
ELOCTATE
Hemophilia Products
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Biogen Revenue by Segment (9/17)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
MS Product Revenues
Interferon
Other corporate revenues
BENEPALI
FAMPYRA
FLIXABI
FUMADERM
ALPROLIX
ELOCTATE
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Biogen Revenue by Segment (10/17)

  • Max

QALSODY
Details
Date
Other corporate revenues
QALSODY
Royalty
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
86.90 M USD
0.00 USD

Biogen Revenue by Segment (11/17)

  • Max

Royalty revenue on sales of OCREVUS
Contract manufacturing revenue
Royalty and other revenue
Details
Date
Royalty revenue on sales of OCREVUS
Contract manufacturing revenue
Royalty and other revenue
Hemophilia Products
Jan 1, 2024
1.34 B USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
679.40 M USD
53.50 M USD
0.00 USD

Biogen Revenue by Segment (12/17)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
TYSABRI
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD

Biogen Revenue by Segment (13/17)

  • Max

SPINRAZA
QALSODY
Details
Date
SPINRAZA
QALSODY
Jan 1, 2024
0.00 USD
32.40 M USD
Jan 1, 2025
1.55 B USD
0.00 USD

Biogen Revenue by Segment (14/17)

  • Max

VUMERITY
Details
Date
VUMERITY
Jan 1, 2024
0.00 USD
Jan 1, 2025
746.80 M USD

Biogen Revenue by Segment (15/17)

  • Max

SPINRAZA
Details
Date
SPINRAZA
Jan 1, 2024
1.57 B USD
Jan 1, 2025
0.00 USD

Biogen Revenue by Segment (16/17)

  • Max

VUMERITY
Details
Date
VUMERITY
Jan 1, 2024
628.00 M USD
Jan 1, 2025
0.00 USD

Biogen Revenue by Segment (17/17)

  • Max

Reportable Segment
Details
Date
Reportable Segment
Jan 1, 2024
9.68 B USD
Jan 1, 2025
9.89 B USD

Biogen Revenue by Region

  • 3 Years

  • 5 Years

  • Max

Foreign
United States
Details
Date
Foreign
United States
Jan 1, 2018
1.40 M USD
-8.60 M USD

Biogen Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biogen historical P/E ratio, EBIT multiple, and P/S ratio

Biogen annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biogen shares outstanding

The number of shares of Biogen was 147.1 M in 2025. This indicates how many shares Biogen is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
150.00 M Stocks
Jan 1, 2022
146.00 M Stocks
Jan 1, 2023
145.60 M Stocks
Jan 1, 2024
145.90 M Stocks
Jan 1, 2025
147.10 M Stocks
Jan 1, 2026 (e)
147.10 M Stocks
Jan 1, 2027 (e)
147.10 M Stocks
Jan 1, 2028 (e)
147.10 M Stocks

Biogen stock splits

In Biogen's history, there have been no stock splits.

Current Biogen forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
8.71 %
Buy
47.62 % (20)
Hold
50.00 % (21)
Sell
2.38 % (1)
12M Price Target
210.12
Last Price
209.83
Currency
USD
12M Return Potential
0.14 %
LTM Return
0 %

Biogen Analyst Rating Actions

DateFirmActionRatingReliability
7/30/2026
Wedbush
Wedbush
MaintainedNeutral59
7/30/2026
UBS
UBS
MaintainedBuy51
7/30/2026
TD Cowen
TD Cowen
MaintainedBuy60
7/30/2026
RBC Capital
RBC Capital
MaintainedOutperform52
7/30/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
7/30/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/30/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
7/29/2026
Barclays
Barclays
MaintainedEqual Weight33
7/21/2026
Guggenheim
Guggenheim
MaintainedBuy30
7/21/2026
B of A Securities
B of A Securities
MaintainedNeutral70

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Biogen Earnings Calls

2025

Biogen Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/29/20263.22USD-2.50 BUSD-2026 Q2
4/29/20263.06USD-2.30 BUSD-2026 Q1
2/6/20261.63USD-2.25 BUSD-2025 Q4
11/6/20244.08USD-2.43 BUSD-2024 Q3
4/23/20243.35USD-2.43 BUSD-2024 Q1
2/13/20243.23USD-2.51 BUSD-2023 Q4
7/18/20234.30USD-2.37 BUSD-2023 Q2
5/1/20234.08USD-2.36 BUSD-2023 Q1
2/1/20233.54USD-2.48 BUSD-2022 Q4
10/25/20224.22USD-2.51 BUSD-2022 Q3
...

EESG©

Eulerpool ESG Scorecard© for the Biogen stock

83/100
88
Environment
81
Social
80
Governance
E

Environment

20
Scope 1 - Direct Emissions56,611
Scope 2 - Indirect emissions from purchased energy32,858
Scope 3 - Indirect emissions within the value chain267,059
Total CO₂ emissions89,469
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees52.5
Percentage of women in management—
Percentage of Asian employees17.7
Share of Asian management19.4
Percentage of Hispanic/Latino employees3.7
Hispano/Latino Management share3.7
Percentage of Black employees11.2
Black Management Share5.5
Percentage of white employees55.6
White Management Share60.1
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Biogen shareholder structure

% Name
11.80673%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
10.85969%
BLACKROCK, INC.
BLACKROCK, INC.
10.03263%
PRIMECAP Management Company
PRIMECAP Management Company
10.03236%
PRIMECAP MANAGEMENT CO/CA/
PRIMECAP MANAGEMENT CO/CA/
8.70669%
FMR LLC
FMR LLC
6.48363%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
...

Biogen Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
17.37%
Biogen MA Inc. 04-3002117
Biogen MA Inc. 04-3002117
SEC ↗
16.70%
Barry N. Wish
Barry N. Wish
SEC ↗
11.30%
FMR LLC
FMR LLC
SEC ↗
10.73%
PRIMECAP Management Company
PRIMECAP Management Company
SEC ↗
10.70%
Biogen Inc.33-0112644
Biogen Inc.33-0112644
SEC ↗
10.21%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
10.20%
PRIMECAP MANAGEMENT CO/CA/
PRIMECAP MANAGEMENT CO/CA/
SEC ↗
9.42%
01-0846058
01-0846058
SEC ↗
9.40%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
8.50%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗

Biogen Executives and Management Board

20 members · avg. age 59 · 45 % women

CV

Mr. Christopher Viehbacher (65)

President, Chief Executive Officer, Director · since 2022

24.17 M USD

Management

SA

Ms. Susan Alexander (68)

Executive Vice President, Chief Legal Officer

6.51 M USD
PS

Dr. Priya Singhal (57)

Executive Vice President, Head of Development

6.39 M USD
NM

Ms. Nicole Murphy (52)

Executive Vice President - Pharmaceutical Operations and Technology

5.74 M USD
RI

Mr. Rachid Izzar (50)

Executive Vice President, Head of Global Product Strategy and Commercialization

5.45 M USD
GG

Dr. Ginger Gregory (57)

Chief Human Resources Officer, Executive Vice President

5.08 M USD
RK

Ms. Robin Kramer (60)

Chief Financial Officer, Executive Vice President

–

Board of Directors

CD

Ms. Caroline Dorsa (66)

Independent Chairman of the Board

629,840.00 USD
WH

Mr. William Hawkins (71)

Independent Director

470,160.00 USD
JM

Mr. Jesus Mantas (56)

Independent Director

469,549.00 USD
ER

Dr. Eric Rowinsky (68)

Independent Director

455,160.00 USD
MF

Dr. Maria Freire (71)

Independent Director

443,771.00 USD
MP

Mr. Monish Patolawala (55)

Independent Director

440,160.00 USD

Biogen Supply Chain

Biogen Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Nameβ 1YTrend
1
AC Immune SA
Supplier·Biotechnology·CH
0.42
0.75
0.72
0.88
0.93
0.74
—
2
Eisai
Supplier·Customer·Pharmaceuticals·JP
0.22
0.31
0.63
0.85
0.89
0.72
1.07
3
InnoCare Pharma
Supplier·Customer·Biotechnology·CN
0.18
0.51
0.43
0.73
0.90
0.69
—
4
E2open Parent Holdings A
Supplier·Software·US
0.20
0.41
0.24
0.71
0.66
0.62
—
5
Catalyst Biosciences
Supplier·Customer·Biotechnology·US
0.46
0.18
0.19
0.62
0.92
0.53
—
#Nameβ 1YTrend
1
2seventy Bio
Supplier·Customer·Biotechnology·US
0.79
0.81
0.77
0.84
—
—
—
2
Ginkgo Bioworks A
Supplier·Customer·Chemicals·US
0.71
0.87
0.79
0.84
0.64
—
—
3
Roche Holding AG
Customer
0.59
0.60
0.75
0.69
0.11
—
—
4
Denali Thrptcs
Supplier·Customer·Biotechnology·US
0.52
0.67
0.55
0.84
0.90
—
1.53
5
Quanterix Corporation
Supplier·Life Sciences Tools & Services·US
0.45
0.64
0.61
0.83
0.89
—
—

Frequently asked questions about Biogen

Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.

Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.

Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.

Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.

Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.

Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.

Analysts currently set an average price target of 210.39 USD for the Biogen stock (median: 210.12 USD), implying +0.3 % versus the latest price. The consensus is based on 42 analyst ratings.

Biogen Analyst Price Targets 2026

43 analysts currently rate the Biogen stock: 20 recommend buying, 22 holding and 1 selling. For 2026, analysts expect Biogen to generate revenue of 10.04 B USD and earnings per share of 12.97 USD.

Biogen Analyst Price Targets 2026

Converted at the current exchange rate, the Biogen share trades at 181.26 EUR (209.83 USD).

The Biogen share (BIIB) is listed on 11 stock exchanges, including: NASDAQ (BIIB), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM), London (0R1B.L), London (0R1B.L).

Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.

The expected revenue of Biogen is 10.04 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biogen is 1.91 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biogen is currently 16.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biogen stock.

The price-to-sales ratio (P/S) of Biogen is currently 3.07. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biogen stock.

The Eulerpool Quality Score for Biogen is 3/10.

The ISIN of Biogen is US09062X1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biogen is 789617. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biogen is BIIB. The ticker symbol is used to trade Biogen shares on the stock exchange.

Biogen paid dividends every year for the past 0 years.

Biogen is assigned to the 'Health' sector.

The dividends of Biogen are distributed in USD.

All fundamentals and in-depth analysis of Biogen

Our stock analysis for Biogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Biogen Stock
Biogen Revenue→
Biogen Stock
Biogen Net Income→
Biogen Stock
Biogen P/E→
Biogen Stock
Biogen P/S→
Biogen Stock
Biogen EBIT→
Biogen Stock
Biogen Dividend→
Biogen Stock
Biogen Directors Dealings→
Biogen Stock
Biogen Stocks→
Biogen Stock
Biogen Market capitalization→
Biogen Stock
Biogen Debt→
Biogen Stock
Biogen Liabilities→
Biogen Stock
Biogen Equity→
Biogen Stock
Biogen AAQS→
Biogen Stock
Biogen Employees→
Biogen Stock
Biogen ROE→
Biogen Stock
Biogen ROA→
Biogen Stock
Biogen ROCE→
Biogen Stock
Biogen News→
Biogen Stock
Biogen Analyst Price Targets→

Health Stocks

Biogend Therapeutics CoBiogaiaBiohavenBiofronteraBiohit OyjBiofronteraBioInfra CoBiofil Chemicals and PharmaceuticalsBioInvent InternationalBiodyne CoBioLASCO Taiwan CoBioDlink International CoAll Stocks A–Z →